<DOC>
	<DOCNO>NCT02779946</DOCNO>
	<brief_summary>Background : Non-alcoholic fatty liver disease ( NAFLD ) hepatic manifestation metabolic syndrome , one major risk factor coronary heart disease ( CHD ) . CHD important manifestation atherosclerosis , immense morbidity mortality . Transient elastography ( TE , Fibroscan® ) include currently develop control attenuation parameter ( CAP ) non-invasive method evaluation liver fibrosis steatosis , already implement routine care patient NAFLD . Hypothesis : The use TE CAP screen NAFLD might easy tool risk assessment CHD . Methods : Patients schedule routine coronary angiography screen manifestation NAFLD TE include CAP , conventional ultrasound , clinical laboratory parameter . Patients stratify presence CHD base angiography result correlation analysis liver fat content perform . NFALD screen validate subgroup MR-based measurement .</brief_summary>
	<brief_title>Non-invasive Liver Screening Risk Assessment Coronary Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>inform consent age ≥ 18 year patient indication routine coronary angiography transplant liver resection right liver lobe transaminase &gt; 5fold upper limit pregnancy lactation choleastasis ultrasound image active malignant consume disease 12 month inclusion congestive heart failure ( EF &lt; 30 % , NYHA III IV , diastolic dysfunction °III IV pulmonary hypertension ( WHO °III IV ) Exclusion criterion MR diagnostics pacemaker ICD non removable magnetizable metal implant claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>